Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

Abstract The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA,
ecstasy) is a popular recreational drug among young people, particularly those involved in …

Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an
efficient way to determine kinase inhibitor specificity by measuring binding of small …

Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid
leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain …

Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …

There has been considerable progress in the systemic treatment of cancer because of the
rapid development and clinical application of molecular targeted agents. Although patients …

Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer
research and therapy. These range from the identification of the first specific chromosomal …

To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it
is important to address the emergence of drug resistance in treated patients. Mutant forms of …

The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …

Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for
cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines …